Clinical practice guidelines for the treatment and management of diabetic macular oedema: a systematic review
Open Access
- 1 October 2025
- journal article
- review article
- Published by Springer Nature in Eye
- Vol. 39 (17) , 3121-3128
Abstract
Background/objectives: To assess geographically global clinical practice guidelines (CPGs) for diabetic macular oedema (DMO) management. Methods: A systematic literature review (SLR) of CPGs for DMO management was conducted using Embase and MEDLINE databases, Guideline Central, Health Technology Assessment bodies, professional ophthalmology associations, and backwards citation tracking. CPGs published between January 2010–October 2023 were included and independently assessed by four reviewers and one adjudicator using the Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument. CPGs were qualitatively assessed for anatomical measurement (optical coherence tomography [OCT]) and visual acuity (VA) recommendations. PROSPERO identification: CRD42023473223. Results: 14/147 identified CPGs were included. Overall AGREE II scores were 49–91 (mean [SD] = 67 [11]). Strongest domains were Scope and Purpose (85 [10.9]), Clarity of Presentation (87 [18.7]), and Editorial Independence (91 [13.7]). Stakeholder Involvement (57 [8.3]), Applicability (54 [19.4]), and Rigor of Development (41 [19.0]) scored lowest. 13/14 CPGs were “Recommended” or “Recommended with Modifications”. All CPGs recommended OCT for initial diagnosis. 3/14 CPGs did not recommend VA or considered VA optional. For initial disease management, 11/14 CPGs recommended OCT. One considered OCT optional. VA was recommended by 9/14 CPGs for initial management. All CPGs recommended using VA and OCT for disease monitoring while on anti-vascular endothelial growth factor therapy. 12/14 CPGs recommended using OCT to measure anti-VEGF response to adjust treatment interval. Conclusion: CPGs were aligned regarding the importance of OCT in DMO management. More rigorous methods, applicability in resource-constrained systems, and patient perspectives will improve CPG trustworthiness and transparency.Keywords
Funding Information
- Genentech
This publication has 46 references indexed in Scilit:
- Optical coherence tomography imaging of macular oedemaBritish Journal of Ophthalmology, 2014
- Anti-vascular endothelial growth factor therapy for diabetic macular edemaTherapeutic Advances in Endocrinology and Metabolism, 2013
- Optical Coherence Tomography in the Diagnosis and Management of Diabetic Macular Edema: Time-Domain Versus Spectral-DomainOphthalmic Surgery, Lasers and Imaging Retina, 2011
- Appraising a tool for guideline appraisal (the AGREE II instrument)Journal of Clinical Epidemiology, 2010
- AGREE II: advancing guideline development, reporting and evaluation in health careCanadian Medical Association Journal, 2010
- Optical coherence tomography of the retina and optic nerve – a reviewClinical & Experimental Ophthalmology, 2009
- Visual fields correlate better than visual acuity to severity of diabetic retinopathyDiabetologia, 2005
- Epidemiology of diabetic retinopathy and macular oedema: a systematic reviewEye, 2004
- Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography*1Ophthalmology, 2004
- Topography of diabetic macular edema with optical coherence tomographyOphthalmology, 1998